Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon J Freeman

Showing results (211-220 of 348) with videos related to

Pageof 35
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell CarcinomaThomas Denize, Yue Hou, Jean-Christophe Pignon, et al.
Nature|November 22, 2017
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillanceJinfang Zhang, Xia Bu, Haizhen Wang, et al.
Cancer Immunology Research|May 28, 2015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaMarcella Callea, Laurence Albiges, Mamta Gupta, et al.
Cancer Immunology Research|October 12, 2021
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune ResponsesXia Bu, Vikram R Juneja, Carol G Reynolds, et al.
Nature|July 5, 2019
Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillanceJinfang Zhang, Xia Bu, Haizhen Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 13, 2025
RGMb drives macrophage infiltration to aggravate kidney diseaseYonglun Kong, Ming Yue, Chunhua Xu, et al.
Cancer Immunology Research|May 20, 2017
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint BlockadeJun Zhou, Kathleen M Mahoney, Anita Giobbie-Hurder, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 5, 2010
Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivityHyun-Hee Lee, Everett H Meyer, Sho Goya, et al.
Cell|February 21, 2012
Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse modelBaochun Zhang, Sven Kracker, Tomoharu Yasuda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2020
Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma TherapyCarmela Passaro, Quazim Alayo, Isabel DeLaura, et al.
Pageof 35

Showing results (211-220 of 348) with videos related to

Sort By:
Pageof 35
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell CarcinomaThomas Denize, Yue Hou, Jean-Christophe Pignon, et al.
Nature|November 22, 2017
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillanceJinfang Zhang, Xia Bu, Haizhen Wang, et al.
Cancer Immunology Research|May 28, 2015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaMarcella Callea, Laurence Albiges, Mamta Gupta, et al.
Cancer Immunology Research|October 12, 2021
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune ResponsesXia Bu, Vikram R Juneja, Carol G Reynolds, et al.
Nature|July 5, 2019
Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillanceJinfang Zhang, Xia Bu, Haizhen Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 13, 2025
RGMb drives macrophage infiltration to aggravate kidney diseaseYonglun Kong, Ming Yue, Chunhua Xu, et al.
Cancer Immunology Research|May 20, 2017
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint BlockadeJun Zhou, Kathleen M Mahoney, Anita Giobbie-Hurder, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 5, 2010
Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivityHyun-Hee Lee, Everett H Meyer, Sho Goya, et al.
Cell|February 21, 2012
Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse modelBaochun Zhang, Sven Kracker, Tomoharu Yasuda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2020
Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma TherapyCarmela Passaro, Quazim Alayo, Isabel DeLaura, et al.
Pageof 35